Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone Clear all
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Obesity in Women Via Estradiol Regulation

NCT00687739
View directory record Official record
Conditions
Obesity
Interventions
leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 12, 2026, 11:03 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 12, 2026, 11:03 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hormones, Outcomes, and Pain Pathways in Exercise Study

NCT07579182
View directory record Official record
Conditions
Breast Pain, Mastalgia, Back Pain, Back Pain, Low, Neck Pain, Chest Pain, Activity, Motor, Healthy Aging, Weight, Body, Inflammation, Gonadal Steroid Hormones, Neuronal Plasticity, Neuromuscular Manifestations
Interventions
Interventional Sports bra
Other
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 12, 2026, 11:03 AM EDT
Terminated Phase 1 Interventional Results available

Growth Hormone Therapy for Wasting in Cystic Fibrosis

NCT00803179
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nutropin AQ
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 12, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Contraceptive Hormones, Immunity, and Microbiome Evaluation

NCT03660046
View directory record Official record
Conditions
Hormonal Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 45 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 12, 2026, 11:03 AM EDT
Completed No phase listed Observational

The Effects of Estrogen Withdrawal on Mood Symptoms in Women

NCT00060736
View directory record Official record
Conditions
Perimenopausal Depression, Post Menopausal, Healthy, Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
45 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Hormone Imbalance

NCT07765381
View directory record Official record
Conditions
Hormone Imbalance, Thyroid Hormone Imbalance, Low Energy, Metabolic Symptoms, Unhealthy Eating Habits
Interventions
Hello Burn, Balance Supplement
Dietary Supplement
Lead sponsor
Love Wellness
Industry
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Not applicable Interventional

CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)

NCT02858336
View directory record Official record
Conditions
Hormones
Interventions
NEA, DEA
Behavioral
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 28 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 12, 2026, 11:03 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NCT02648477
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Anastrozole, Doxorubicin Hydrochloride, Exemestane, Laboratory Biomarker Analysis, Letrozole, Pembrolizumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Corona, California • Duarte, California • Lancaster, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 12, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional

Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

NCT00104130
View directory record Official record
Conditions
Prostate Cancer
Interventions
KOS-862
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
9
States / cities
Vallejo, California • Tucker, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00118092
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
tanespimycin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 12, 2026, 11:03 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264
View directory record Official record
Conditions
Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions
BG-68501, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 12, 2026, 11:03 AM EDT
Not listed Phase 3 Interventional

A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

NCT06007417
View directory record Official record
Conditions
GHD
Interventions
GenSci004, Genotropin
Drug
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 12, 2026, 11:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

NCT00510718
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
MDV3100
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
9
States / cities
Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 12, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

NCT00044252
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hormones and Decision Making

NCT04865562
View directory record Official record
Conditions
Dyssocial Behavior
Interventions
testosterone propionate, 0.5% cholorbutanol, saline
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 12, 2026, 11:03 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effects of Aging and Estrogen on the Pituitary

NCT00386022
View directory record Official record
Conditions
Healthy
Interventions
GnRH, NAL-GLU GnRH antagonist, Estrogen patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer

NCT03949270
View directory record Official record
Conditions
Breast Cancer, Adherence, Medication, Side Effect
Interventions
BETA-Text text messaging intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 12, 2026, 11:03 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

NCT00765323
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide Implant, Sandostatin LAR Depot
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 12, 2026, 11:03 AM EDT
Completed No phase listed Observational

Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy

NCT01539486
View directory record Official record
Conditions
Parathyroid Disease
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 12, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture

NCT02375503
View directory record Official record
Conditions
Bone Alteration, Dietary Modification
Interventions
Calcium/Vitamin D, Placebo
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
17 Years to 42 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 12, 2026, 11:03 AM EDT